Agonists, Antagonists and Receptors of Somatostatin: Pathophysiological and Therapeutical Implications in Neoplasias
Argyrios Periferakis,Georgios Tsigas,Aristodemos-Theodoros Periferakis,Carla Mihaela Tone,Daria Alexandra Hemes,Konstantinos Periferakis,Lamprini Troumpata,Ioana Anca Badarau,Cristian Scheau,Ana Caruntu,Ilinca Savulescu-Fiedler,Constantin Caruntu,Andreea-Elena Scheau
DOI: https://doi.org/10.3390/cimb46090578
2024-09-02
Abstract:Somatostatin is a peptide that plays a variety of roles such as neurotransmitter and endocrine regulator; its actions as a cell regulator in various tissues of the human body are represented mainly by inhibitory effects, and it shows potent activity despite its physiological low concentrations. Somatostatin binds to specific receptors, called somatostatin receptors (SSTRs), which have different tissue distributions and associated signaling pathways. The expression of SSTRs can be altered in various conditions, including tumors; therefore, they can be used as biomarkers for cancer cell susceptibility to certain pharmacological agents and can provide prognostic information regarding disease evolution. Moreover, based on the affinity of somatostatin analogs for the different types of SSTRs, the therapeutic range includes conditions such as tumors, acromegaly, post-prandial hypotension, hyperinsulinism, and many more. On the other hand, a number of somatostatin antagonists may prove useful in certain medical settings, based on their differential affinity for SSTRs. The aim of this review is to present in detail the principal characteristics of all five SSTRs and to provide an overview of the associated therapeutic potential in neoplasias.